Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors

BACKGROUND: Preclinical studies indicate that the concurrent use of inhibitors of the renin–angiotensin–aldosterone system (RAAS) may improve outcomes in broad groups of patients with cancer. There are limited data on the association between the use of RAAS inhibitors and outcomes among patients tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Drobni, Zsofia D., Michielin, Olivier, Quinaglia, Thiago, Zlotoff, Daniel A., Zubiri, Leyre, Gilman, Hannah K., Supraja, Sama, Merkely, Bela, Muller, Veronika, Sullivan, Ryan J., Reynolds, Kerry L., Pittet, Michael J., Jain, Rakesh K., Neilan, Tomas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618285/
https://www.ncbi.nlm.nih.gov/pubmed/35065368
http://dx.doi.org/10.1016/j.ejca.2021.12.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618285/
https://www.ncbi.nlm.nih.gov/pubmed/35065368
http://dx.doi.org/10.1016/j.ejca.2021.12.024

Ejemplares similares